Literature DB >> 9313886

Haematopoietic transplantation in pulmonary alveolar proteinosis associated with chronic myelogenous leukaemia.

M Rodríguez-Luaces1, A Lafuente, M P Martín, P Mateos, E Ojeda, F Hernández-Navarro.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a disease of unknown etiopathogenesis sometimes associated with malignant haematological disorders. The potential reversibility of the process in these cases seems to be related to recovery from the underlying disease. GM-CSF has acquired an important, potentially pathogenic role and BMT presents one therapeutic option effective in certain forms of human PAP. We present the case of a 43-year-old female patient with Ph+ CML. During pretransplantation evaluation, unexpected pulmonary infiltrates were noted in the chest X-ray, PAP being diagnosed on biopsy. In view of the progressive respiratory symptomatology and her CML being in accelerated phase, the patient underwent haematopoietic transplantation. She died on day +12 from invasive pulmonary aspergillosis before a response could be observed. Pathogenic implications in PAP and the role of haematopoietic transplantation in this disease are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9313886     DOI: 10.1038/sj.bmt.1700915

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Successful allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by severe pulmonary alveolar proteinosis.

Authors:  Sumie Tabata; Sonoko Shimoji; Kimihiko Murase; Yoko Takiuchi; Daichi Inoue; Takaharu Kimura; Yuya Nagai; Minako Mori; Katsuhiro Togami; Masayuki Kurata; Kiminari Ito; Hisako Hashimoto; Akiko Matushita; Kenichi Nagai; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2009-08-20       Impact factor: 2.490

2.  High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease.

Authors:  A Sergeeva; Y Ono; R Rios; J J Molldrem
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.